The worldwide epidemic of obesity and its medical complications are being handled a combined mix of lifestyle changes ( em e. individuals which have undergone RYGB. A plausible hypothesis to describe this observation can be that the gastric bypass surgical treatment instead of the gastric banding treatment impinges on glucose homeostasis by a pounds loss-independent system. In a recently available paper, Bradley et al possess experimentally explored this hypothesis. The authors in comparison several medical and laboratory parameters of insulin sensitivity and -cellular function in cohorts of RYGB and LAGB individuals before and once they lost around 20% of their body mass. After pounds loss, both LIT sets of individuals underwent similar adjustments within their intra-abdominal and total adipose cells quantity, hepatic triglyceride and circulating leptin amounts. The RYGB individuals who lost 20% body mass, manifested higher postprandial result of glucose, insulin and glucagon-like peptide-1; these laboratory parameters remained unchanged in LABG individuals. Regardless of the noticed variations in transient responses of RYGB and LAGB individuals to mixed food, the entire glycemic control as judged by glucose tolerance, multi-organ insulin sensitivity and -cellular function were almost identical in both organizations. Both RYGB and LAGB individual cohorts also experienced comparable adjustments in the expression of several pro- and anti-inflammatory markers. Predicated on these analyses, Bradley et al figured comparable restoration of insulin sensitivity and b-cell function in nondiabetic obese patients which have undergone RYGB and LAGB had been directly because of marked weight reduction. These data possess essential implications for the risk/benefit evaluation of weight reduction therapy by bariatric methods. strong course=”kwd-name” Keywords: Bariatric surgical treatment, Roux-en Y gastric bypass, Laparoscopic adaptable gastric banding, Pounds reduction, Type-2 diabetes Primary tip: This record demonstrates that the results of Roux-en Y gastric bypass and laparoscopic adaptable gastric banding are primarily due to weight reduction. Quantitatively comparable losses of intra-stomach and total adipose had been observed in both sets of individuals who also experienced improved glucose tolerance, multi-organ insulin sensitivity and -cellular function. Weight reduction was connected with positive adjustments in a number of Arranon manufacturer pro- and anti-inflammatory markers, regardless of the type of gastric surgery. In light of these findings the risk/benefit ratio of weight loss therapy by bariatric procedures with varying degrees of invasiveness, post-surgical complications and cost need to be re-evaluated. COMMENTARY ON HOT TOPICS Arranon manufacturer Obesity-associated type-2 diabetes mellitus (T2DM) and metabolic syndrome, and the cardiovascular consequences of chronic obesity are steadily emerging as key global healthcare challenges of the 21st century (World Health Organization Global Infobase: data on overweight and obesity mean body mass index, healthy diets and physical inactivity; www.who.int/mediacenter/). Surgical procedures such as gastric banding, gastric bypass and bilio-pancreatic diversion/duodenal switch have proven to be highly effective therapies for weight loss in morbidly obese individuals[1-4]. Regardless of whether weight loss is achieved by a combination of diet and/or exercise, or by surgery, such interventions, invariably, lead to improved metabolic profiles and amelioration of diabetes. A comprehensive review and meta-analysis of 621 studies involving different types of bariatric surgeries revealed that a vast majority of patients that underwent weight loss following these procedures also experienced improvement in the clinical and laboratory manifestations of their diabetes[5]. Furthermore, it was noted that the improved glucose homeostasis and weight loss were progressively more significant with laparoscopic adjustable gastric banding (LAGB), gastroplasty, Roux-en-Y gastric bypass (RYGB) and bilio-pancreatic diversion/duodenal switch procedures[5]. Whether variable metabolic outcome of different types Arranon manufacturer of bariatric procedures is caused by weight loss alone or involves other factors remains controversial. Two common bariatric surgeries used for weight loss therapy are RYGB that diverts the ingested food from passage through the upper gastrointestinal (GI) tract[6] and the laparoscopic adjustable gastric banding (LAPG) technique that reduces the size of the stomach[7]. The meta-analytical observations of Buchwald et al[5] and a number of other experimental findings have led some investigators to question the exclusive cause and effect relationship between weight loss and diabetes in individuals undergoing bariatric.